Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants.

Blood
Per LjungmanValacyclovir International Bone Marrow Transplant Study Group

Abstract

Oral valacyclovir for cytomegalovirus (CMV) prophylaxis in bone marrow transplantation (BMT) was investigated in a randomized, double-blind, acyclovir-controlled, multicenter clinical trial in recipients of allogeneic BMT who were CMV seropositive (or donor positive) before transplantation and were aged 13 years or older. Patients were randomized before BMT. All initially received intravenous acyclovir (500 mg/m(2)) 3 times daily until day 28 after transplantation or after discharge, then oral valacyclovir (2 g) or acyclovir (800 mg) 4 times daily until week 18 after transplantation. Evidence of CMV infection, CMV disease, and death were documented for 22 weeks. Primary end points were time to CMV infection (detection of CMV in blood, broncho-alveolar lavage) or CMV disease and survival. Preemptive CMV therapy was permitted. Seven hundred twenty-seven patients were evaluable for efficacy. After the administration of intravenous acyclovir, valacyclovir was significantly more effective than oral acyclovir in reducing the incidence of CMV infection. CMV infection or disease developed in 102 (28%) valacyclovir patients, compared with 143 (40%) acyclovir patients (HR, 0.59; 95% CI, 0.46-0.76; P <.0001). Survival did not differ betwe...Continue Reading

References

Jun 1, 1991·The Journal of Clinical Investigation·W HeagyR W Finberg
Jan 14, 1988·The New England Journal of Medicine·J D MeyersE D Thomas
Oct 1, 1988·Transplantation·L BoströmB Nilsson
Sep 1, 1983·The Journal of Antimicrobial Chemotherapy·P de Miranda, M R Blum
Aug 3, 1999·Antimicrobial Agents and Chemotherapy·C L TalaricoK K Biron
Jun 29, 2001·Transplant Infectious Disease : an Official Journal of the Transplantation Society·L BarkholtJ Andersson

❮ Previous
Next ❯

Citations

May 23, 2006·Intensive Care Medicine·Elie Azoulay, Benoît Schlemmer
Sep 25, 2003·Journal of Cutaneous Medicine and Surgery·Jashin J WuStephen K Tyring
Apr 24, 2010·International Journal of Hematology·Takehiko Mori, Jun Kato
Apr 10, 2004·The International Journal of Biochemistry & Cell Biology·Karl S Peggs, Stephen Mackinnon
Nov 9, 2002·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·S M L WaughW F Carman
Jul 26, 2003·Paediatric Respiratory Reviews·Alexandra Soldatou, E Graham Davies
Jul 9, 2002·British Journal of Haematology·Per Ljungman
Oct 2, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·John A Zaia
Sep 28, 2002·The Journal of Infectious Diseases·Jean-Paul Squifflet, Christophe Legendre
Sep 28, 2002·The Journal of Infectious Diseases·Per Ljungman
Sep 8, 2011·International Ophthalmology Clinics·Anthony B DanielsLucy H Y Young
Oct 15, 2003·Clinical Microbiology Reviews·Ellen MeijerLeo F Verdonck
Mar 21, 2009·Blood·Michael Boeckh, Per Ljungman
Apr 9, 2011·Herpesviridae·Stefania Varani, Maria Paola Landini
Dec 21, 2002·American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons·Julien BaudBruno Hurault de Ligny
Oct 16, 2004·Expert Review of Anti-infective Therapy·Karl S Peggs
Dec 2, 2004·Expert Opinion on Emerging Drugs·Arun ChakrabartyStephen K Tyring
Jun 2, 2012·Expert Opinion on Biological Therapy·Rob S Sellar, Karl S Peggs
Jan 7, 2016·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Yao ChenXiao-Jun Huang
Mar 24, 2012·Current Opinion in Virology·Francisco M Marty, Michael Boeckh
Jan 18, 2011·Hematology/oncology Clinics of North America·Per LjungmanMichael Boeckh
Jul 30, 2010·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Hubertus C E BuyckVincent C Emery
May 15, 2010·Infectious Disease Clinics of North America·Per LjungmanMichael Boeckh
Oct 3, 2009·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Dafna YahavMical Paul
Nov 3, 2005·Clinics in Chest Medicine·Michael G Ison, Jay A Fishman
Oct 29, 2015·Immunotherapy·Taiga NishihoriMohamed A Kharfan-Dabaja
Jul 3, 2008·Oral Diseases·M M ImanguliJ C Atkinson
Dec 23, 2011·British Journal of Haematology·Rob S Sellar, Karl S Peggs
Jul 16, 2015·Cellular and Molecular Life Sciences : CMLS·Miriam CiáurrizNatalia Ramírez
Jun 3, 2004·Human Immunology·Holger Hebart, Hermann Einsele
Apr 12, 2016·Bone Marrow Transplantation·C A ClarkB N Savani
Jan 10, 2006·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·William B ErshlerEvan T Keller
Dec 23, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Xiaojin WuYuejun Liu
Sep 15, 2009·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Marcie TomblynUNKNOWN Centers for Disease Control and Prevention

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.